NO20076191L - Magnesiumsalter av HMG-COA reduktaseinhibitorer - Google Patents

Magnesiumsalter av HMG-COA reduktaseinhibitorer

Info

Publication number
NO20076191L
NO20076191L NO20076191A NO20076191A NO20076191L NO 20076191 L NO20076191 L NO 20076191L NO 20076191 A NO20076191 A NO 20076191A NO 20076191 A NO20076191 A NO 20076191A NO 20076191 L NO20076191 L NO 20076191L
Authority
NO
Norway
Prior art keywords
hmg
coa reductase
magnesium salts
reductase inhibitors
compositions
Prior art date
Application number
NO20076191A
Other languages
English (en)
Norwegian (no)
Inventor
Yatendra Kumar
Swargam Sathyanarayana
Saridim Madhava Dileep Kumar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076191(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of NO20076191L publication Critical patent/NO20076191L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20076191A 2005-05-03 2007-11-30 Magnesiumsalter av HMG-COA reduktaseinhibitorer NO20076191L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1108DE2005 2005-05-03
PCT/IB2006/051396 WO2006117761A2 (fr) 2005-05-03 2006-05-03 Sels de magnesium d'inhibiteurs de hmg-coa reductase

Publications (1)

Publication Number Publication Date
NO20076191L true NO20076191L (no) 2008-01-30

Family

ID=37308379

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076191A NO20076191L (no) 2005-05-03 2007-11-30 Magnesiumsalter av HMG-COA reduktaseinhibitorer

Country Status (9)

Country Link
US (1) US20100222405A1 (fr)
EP (2) EP2172452A1 (fr)
AT (1) ATE496025T1 (fr)
DE (1) DE602006019710D1 (fr)
DK (1) DK1879862T3 (fr)
ES (1) ES2304911T3 (fr)
NO (1) NO20076191L (fr)
PT (1) PT1879862E (fr)
WO (1) WO2006117761A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084488B2 (en) 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
US20100168201A1 (en) * 2005-11-29 2010-07-01 Biocan Limited Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1)
WO2007099552A2 (fr) * 2006-03-02 2007-09-07 Matrix Labaratories Ltd Nouvelle forme cristalline d'atorvastatine hémi-magnésium
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
IS8587A (is) * 2006-12-27 2008-06-28 Actavis Group Hf. Atorvastatin lyfjasamsetning
WO2009063476A1 (fr) * 2007-11-16 2009-05-22 Biocon Limited Forme cristalline du sel d'hémi-magnésium d'atorvastatine et son procédé de préparation
EP2130819A3 (fr) 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Formules cristallines de magnésium d'atorvastatine
WO2009157005A1 (fr) * 2008-06-26 2009-12-30 Biocon Limited Formes cristallines d’un sel d’hémi-magnésium d’atorvastatine et son procédé

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2413702A1 (fr) * 2000-06-28 2002-01-03 Teva Pharmaceuticals Industries Ltd. Carvedilol
KR20040101229A (ko) * 2002-02-14 2004-12-02 랜박시 래보러터리스 리미티드 알칼리 금속 첨가에 의해 안정화된 아토르바스타틴 배합물
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
WO2006070248A1 (fr) * 2004-12-28 2006-07-06 Ranbaxy Laboratories Limited Procedes permettant de preparer des formes posologiques pharmaceutiques solides et stables a base d'atorvastatine et d'amlodipine
WO2006084474A2 (fr) * 2005-02-10 2006-08-17 Lifecycle Pharma A/S Preparation pharmaceutique stable comprenant une dose fixe de fenofibrate et d'un inhibiteur de la hmg-coa reductase
US8084488B2 (en) * 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
US20100168201A1 (en) * 2005-11-29 2010-07-01 Biocan Limited Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1)
WO2007099552A2 (fr) * 2006-03-02 2007-09-07 Matrix Labaratories Ltd Nouvelle forme cristalline d'atorvastatine hémi-magnésium
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
CN101516842A (zh) * 2006-05-11 2009-08-26 百康有限公司 阿托伐他汀镁晶型b4及其方法
EP2130819A3 (fr) * 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Formules cristallines de magnésium d'atorvastatine

Also Published As

Publication number Publication date
DK1879862T3 (da) 2011-05-16
DE602006019710D1 (de) 2011-03-03
EP1879862A2 (fr) 2008-01-23
US20100222405A1 (en) 2010-09-02
WO2006117761A2 (fr) 2006-11-09
ES2304911T3 (es) 2011-05-30
PT1879862E (pt) 2011-04-19
ES2304911T1 (es) 2008-11-01
EP2172452A1 (fr) 2010-04-07
WO2006117761A3 (fr) 2007-03-29
EP1879862B1 (fr) 2011-01-19
ATE496025T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
NO20076191L (no) Magnesiumsalter av HMG-COA reduktaseinhibitorer
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20084435L (no) C-MET proteinkinaseinhibitorer
WO2008033562A3 (fr) Composés inhibiteurs de kinases
NO20064852L (no) Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser
TW200616953A (en) Indole, indazole or indoline derivatives
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
NO20074446L (no) DR5-antistoffer og anvendelser derav
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EA200801008A1 (ru) Гипохолестеринемические соединения
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application